Post hoc health-related quality of life analysis according to response among patients with prostate cancer in the PROSELICA and FIRSTANA studies.
Fiche publication
Date publication
avril 2021
Journal
The oncologist
Auteurs
Membres identifiés du Cancéropôle Est :
Dr THIERY-VUILLEMIN Antoine
Tous les auteurs :
Thiery-Vuillemin A, Fizazi K, Sartor O, Oudard S, Bury D, Ozatilgan A, Poole EM, Eisenberger M, de Bono J
Lien Pubmed
Résumé
The phase III PROSELICA (NCT01308580) and FIRSTANA (NCT01308567) trials investigated taxane chemotherapy among men with post-docetaxel metastatic castration-resistant prostate cancer (mCRPC) or chemotherapy-naïve mCRPC, respectively. We present a post hoc analysis of patient reported health-related quality of life (HRQL) among patients with or without a clinical (pain, tumor or prostate-specific antigen [PSA]) response.
Mots clés
HRQL, Prostate, cabazitaxel, docetaxel, mCRPC, pain
Référence
Oncologist. 2021 Apr 27;: